Can Etrasimod-Velsipity completely cure ulcerative colon?

Ulcerative colitis (UC) is a typical chronic inflammatory bowel disease. Its pathogenesis involves complex links such as abnormal immune response, intestinal flora imbalance, genetic factors and environmental influences. At present, the medical community has not found a complete cure for UC. Treatment goals mainly focus on relieving symptoms, promoting mucosal healing, reducing recurrence, and improving patients' long-term quality of life.

Etrasimod (Etrasimod), as an S1P receptor modulator, can reduce the number of inflammatory cells entering the intestine by limiting the migration of immune cells from lymph nodes, thereby alleviating the inflammatory response. Studies have shown that the drug can improve patients' symptoms such as abdominal pain, diarrhea, and bloody stools in a short period of time, and at the same time help maintain remission and reduce disease activity during the maintenance treatment phase. This means that Velsipity can significantly improve the quality of life of UC patients and extend the period of disease-free activity.

However, from a radical cure perspective, itridimod cannot completely eliminate the cause ofUC. Its function is mainly to control the abnormal activity of the immune system, rather than to reverse the genetic background or completely restore the intestinal immune balance. In other words, it is immunomodulation to achieve long-term remission rather than a final cure. At present, the global medical community is still in the exploratory stage for the cure of UC, including stem cell therapy, gene editing and more precise targeting strategies, but they are still in experimental or early clinical stages.

Nevertheless, the significance of itridimod is to provide a long-term controllable, high-compliance, and clear-efficacy treatment regimen. Compared with traditional glucocorticoids, it has a lower risk of side effects; compared with some biologics, its oral form is more convenient and shows greater potential in maintaining remission. For patients with refractory or relapsed UC, the application of itrimod can effectively delay disease progression, reduce surgical risks, and reduce the burden of long-term hospitalization and complications.

Reference materials:https://www.drugs.com/mtm/etrasimod.html